Patients are selected for treatment with Lynparza based on an FDA-approved genetic test. "This class of drugs has been used to treat advanced, BRCA-mutated ovarian cancer and has now shown efficacy in treating certain types of BRCA-mutated breast cancer," said Richard Pazdur, director of the...
[3]https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-irinotecan-liposome-first-line-treatment-metastatic-pancreatic-adenocarcinoma [4]https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approve...
FDA approves test for ovarian cancer.The article reports that the OVA1 test of the Vermillion Inc. has been approved by the U.S. Food and Drug Authority (FDA) to help practitioners determine ovarian cancer in a pelvic mass.EBSCO_AspNurse Practitioner...
参考资料: [1] https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-mirvetuximab-soravtansine-gynx-fra-positive-platinum-resistant [2] Wills B, Fan Q, Alexander C, et al. Confusion following Tr...
AbbVie’s antibody-drug conjugate Elahere on Friday won the FDA’s full approval for the treatment of FRα-positive, platinum-resistant ovarian, fallopian tube and primary peritoneal cancers.
[1] LYNPARZA® (olaparib) Approved by US FDA for First-Line Maintenance Therapy in BRCA-mutated Advanced Ovarian Cancer. Retrieved December 20, 2018, from https://www.businesswire.com/news/home/20181219005789/en/LYNPARZA%C2%AE-olaparib-Approved-FDA-First-Line-Maintenance-Therapy ...
Elahere’s approval is a long-awaited milestone in the treatment of advanced ovarian cancers. Advertisement FDA Approves New Type of Immunotherapy for Early Bladder Cancer Anktiva, an IL-15 agonist, also shows promise for other malignancies, including non-small-cell lung cancer, and even for...
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-advanced-endometrial-carcinoma [15]ImmunoGen Announces FDA Accelerated Approval of ELAHERE™ (mirvetuximab soravtansine-gynx) for the ...
The Food and Drug Administration approved niraparib, a poly ADP ribose polymerase (PARP) inhibitor, on March 27, 2017, for maintenance treatment of patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response to platinum-based chemotherapy. Approval wa...
Prior authorization for FDA-approved PARP inhibitors in ovarian cancer doi:10.1016/j.gore.2024.101335InsuranceMedicareMedicaidOvarian cancerPARP inhibitorsPrior AuthorizationGynecologic Oncology Case ReportsAnna Jo Bodurtha SmithAnnie AppleAudra HugoAshley HaggertyEmily M. Ko...